Benign prostatic hyperplasia: An insight into current investigational medical therapies

Expert Opinion on Investigational Drugs

Volumn 14, Issue 11, 2005, Pages 1359-1372

  Tiwari, Atul ^a   Krishna, N S ^a   Nanda, Kamna ^a   Chugh, Anita ^a  

^a RANBAXY RESEARCH LABORATORIES   (India)

Author keywords

blockers; BPH; Combination therapy; Emerging therapies; LUTS

Indexed keywords

2 [3 (1,4 BENZODIOXAN 2 YLMETHYLAMINO)PROPYL] 3(2H) PYRIDAZINONE; 3 [3 [4 [4 FLUORO 2 (2,2,2 TRIFLUOROETHOXY)PHENYL] 1 PIPERAZINYL]PROPYL] 5 METHYL 1H PYRIMIDINE 2,4 DIONE; 4 [3 [3 [BIS(4 ISOBUTYLPHENYL)METHYLAMINO]BENZOYL] 1H INDOL 1 YL]BUTYRIC ACID; AIO 8507L; ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROGEN; AZASTERIDE; COLECALCIFEROL DERIVATIVE; CYOCTOL; CYPROTERONE; DOXAZOSIN; DUTASTERIDE; ENZYME INHIBITOR; EPRISTERIDE; FIDUXOSIN; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; HEXOKINASE; OXYTOCIN ANTAGONIST; SILODOSIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; UK 294315; UK 338003; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZANOTERONE;

ADRENERGIC ACTIVITY; CLINICAL TRIAL; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; EJACULATION DISORDER; GENE THERAPY; GERIATRIC PATIENT; GYNECOMASTIA; HORMONAL REGULATION; HUMAN; IMPOTENCE; LIBIDO DISORDER; MALE; MALE SEXUAL DYSFUNCTION; MICTURITION DISORDER; NONHUMAN; PATHOPHYSIOLOGY; PHOTODYNAMIC THERAPY; PROSTATE HYPERTROPHY; PROSTATITIS; REVIEW; SAFETY; SIDE EFFECT; SMOOTH MUSCLE CONTRACTION; TREATMENT INDICATION; URETHRA OBSTRUCTION;

ADRENERGIC ALPHA-ANTAGONISTS; ANDROGEN ANTAGONISTS; CHOLESTENONE 5 ALPHA-REDUCTASE; DRUG THERAPY, COMBINATION; GENE THERAPY; GONADOTROPIN-RELEASING HORMONE; HEXOKINASE; HUMANS; MALE; OXYTOCIN; PHOTOCHEMOTHERAPY; PROSTATIC HYPERPLASIA; RECEPTORS, ANDROGEN;

EID: 27744470982     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.11.1359     Document Type: Review

References (85)

1. MARCELLI M, CUNNINGHAM GR: Hormonal signaling in prostatic hyperplasia and neoplasia. J. Clin. Endocrinol. Metab. (1999) 84:3463-3468.
2. CAINE M: The present role of α-adrenergic blockers in the treatment of benign prostatic hypertrophy. J. Urol. (1986) 136(1):1-4.
3. HIEBLE JP, CAINE M, ZALAZNIK E: In vitro characterization of the α-adrenoceptors in human prostate. Eur. J. Pharmacol. (1985) 107(2):111-117.
4. CAINE M, RAZ S, ZEIGLER M: Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br. J. Urol. (1975) 47(2):193-202.
5. LEPOR H, GUP DI, BAUMANN M, SHAPIRO E: Laboratory assessment of terazosin and α-1 blockade in prostatic hyperplasia. Urology (1988) 32(6):21-26.
6. GUP DI, SHAPIRO E, BAUMANN M, LEPOR H: Contractile properties of human prostate adenomas and the development of infravesical obstruction. Prostate (1989) 15(2):105-114.
7. 1 adrenergic receptors in human benign prostatic hyperplasia. J. Urol. (1984) 132(6):1226-1229.
8. YAMADA S, ASHIZAWA N, USHIJIMA H, NAKAYAMA K, HAYASHI E, HONDA K: α1 adrenoceptors in human prostate: characterization and alteration in benign prostatic hypertrophy. J. Pharmacol. Exp. Ther. (1987) 242(1):326-330.
9. 1 adrenoceptors using radioligand receptor binding on slide-mounted issue section. J. Urol. (1993) 150(6):2002-2006.
10. FURUYA S, KUMAMOTO Y, YOKOYAMA E, TSUKAMOTO T, IZUMI T, ABIKO Y: α-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J. Urol. (1982) 128(4):836-839.
11. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology (2004) 64(6):1081-1088.
12. MILANI S, DJAVAN B: Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on α-adrenoceptor antagonists. BJU Int. (2005) 95:29-36.
13. LEE M: Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia. Am. J. Health Syst. Pharm. (2003) 60(14):1426-1439.
14. JACOBSEN SJ, JACOBSON DJ, GIRMAN CJ et al.: Natural history of prostatism: risk factors for acute urinary retention. J. Urol. (1997) 158(2):481-487.
15. KMD 3213, KAD 3213, silodosin. Drugs R D (2004) 5(1):50-51.
16. WYLLIE MG: Uroselectivity: end of the road? BJU Int. (2003) 92:141-142.
17. DIOKNO AC: Benign changes in the prostate with ageing. Br. J. Urol. (1998) 82(Suppl. 1):44-46.
18. GRAYHACK JT, KOZLOWSKI JM, LEE C: The pathogenesis of benign prostatic hyperplasia: a proposed hypothesis and critical evaluations. J. Urol. (1998) 160:2375-2380.
19. BUTTYAN R, SHABSIGH A, PERLMAN H, COLOMBEL M: Regulation of apoptosis in the prostate gland by androgenic steroids. Trends Endocrinol. Metab. (1999) 10(2):47-54.
20. ISAACS JT: Antagonistic effect of androgen on prostatic cell death. Prostate (1984) 5(5):545-557.
21. CARSON C, RITTMASTER R: The role of dihydrotestosterone in benign prostatic hyperplasia. Urology (2003) 61(Suppl. 4A):2-7.
22. GEORGE FW, CARR BR, NOBLE JF, WILSON JD: 5-α reduced androgens in the human fetal testis. J. Clin. Endocrinol. Metab. (1987) 64(3):628-630.
23. SPAN PN, SCHALKEN JA, SWEEP FG, SMALS AG: Identification and partial characterization of two steroid 5 α-reducatse isozymes in the canine prostate. Prostate (1998) 34(3):222-230.
24. PELLETIER G, LUU-THE V, HUANG XF, LAPOINTE H, LABRIE F: Localization by in situ hybridization of steroid 5 α-reductase isozyme gene expression in the human prostate and preputial skin. J. Urol. (1998) 160:582-587.
25. BARTSCH G, RITTMASTER RS, KLOCKER H: Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia. World J. Urol. (2002) 19:413-425.
26. GLASSMAN DT, CHON JK, BORKOWSKI A, JACOBS SC, KYPRIANOU N: Combined effect of terazosin and finasteride on apoptosis, cell proliferation and transforming growth factor-beta expression in benign prostatic hyperplasia. Prostate (2001) 46(1):45-51.
27. ANDRIOLE GL, KIRBY R: Safety and tolerability of the dual 5α-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur. Urol. (2003) 44:82-88.
28. ROEHRBORN CG, BOYLE P, NICKEL JC et al.: Efficacy and safety of a dual inhibitor of 5-α-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology (2002) 60 (3):434-441.
29. McCONNELL JD, BRUSKEWITZ R, WALSH P et al.: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl. J. Med. (1998) 338 (9):557-563.
30. LEPOR H, WILLIFORD WO, BARRY MJ et al.: For the Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group: the efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N. Engl. J. Med. (1996) 335:533-539.
31. KIRBY R, BOYLE P, ROEHRBORN C: Results of PREDICT (Prospective Randomized European Doxazosin and Combination) study of medical therapy for BPH. Br. J. Urol. (1999) 83:83 (Abstract).
32. CALAIS DA SILVA F, MARQUIS P. DESCHASEAUX P, GINESTE JL, CAUQUIL J, PATRICK DL: Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study. Eur. Urol. (1997) 31:272-280.
33. SUN ZY, FENG J, QUI XD, WU HY, ZHENG WJ, TU ZH: Reversible long-term toxicity of epristeride in beagle dogs. Toxicol. Appl. Pharmacol. (1999) 154(2):145-152.
34. BERREVOETS CA, UMAR A, BRINKMANN AO: Antiandrogens: selective androgen receptor modulators. Mol. Cell Endocrinol. (2002) 198:97-103.
35. BERGER BM, NAADIMUTHU A, BODDY A et al.: The effect of zanosterone, a steroidal androgen receptor antagonist, in men with benign prostatic hyperplasia. The Zanosterone Study Group. J. Urol. (1995) 154(3):1060-1064.
36. CONN PM, CROWLEY WF Jr: Gonadotropin-releasing hormone and its analogs. Ann. Rev. Med. (1994) 45:391-405.
37. KARTEN MJ, RIVIER JE: Gonadotropin-releasing hormone analog design - structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocr. Rev. (1986) 7:44-66.
38. EVANS CP, FLESHNER N, FITZPATRICK JM, ZLOTTA AR: An evidence-based approach to understanding the pharmacological class effect in the management of prostatic diseases. BJU Int. (2005) 95:743-749.
39. SCHLEGEL PN, BRENDLER CB: Management of urinary retention due to benign prostatic hyperplasia using leutenizing hormone-releasing hormone agonist. Urology (1989) 34(2):69-72.
40. BOSCH RJ, GRIFFITHS DJ, BLOM JH, SCHROEDER FH: Treatment of benign prostatic hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters. J. Urol. (1989) 141(1):68-72.
41. OESTERLING JE: LHRH agonists. A nonsurgical treatment for benign prostatic hyperplasia. J. Androl. (1991) 12(6):381-388.
42. ERI LM, TVETER KJ: A prospective, placebo-controlled study of the leuteinizing hormone-releasing hormone agonist leuprolide as treatment for patients with benign prostatic hyperplasia. J. Urol. (1993) 150(2):359-364.
43. PALLAS P, PARADA G: Treatment of acute urinary retention caused by benign prostatic hypertrophy with an LH-RH agonist (goserelin). Actas Urol. Esp. (1995) 19(2):118-122.
44. CROOK T, SHERIDAN WP: Development of GnRH antagonists for prostate cancer: New approaches to treatment. Oncologist (2000) 5:162-168.
45. WILLIAMS MB, HERNANDEZ J, THOMPSON I: Leuteinizing hormone-releasing hormone agonist effects on skeletal muscle: how hormonal therapy in prostate cancer affects muscular strength. J. Urol. (2005) 173(4):1067-1071.
46. WECKERMANN D, HARZMANN R: Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. Eur. Urol. (2004) 46:279-284.
47. HUIRNE JA, LAMBALK CB: Gonadotropin-releasing-hormone-receptor antagonists. Lancet (2001) 358:1793-1803.
48. COMARU-SCHALLY AM, BRANNAN W, SCHALLY AV, COLCOLOUGH M, MONGA M: Efficacy and safety of leutenizing hormone-releasing antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. J. Clin. Endocrinol. Metab. (1998) 83:3826-3831.
49. COSTELLO LC, FRANKLIN RB: Testosterone and prolactin regulation of metabolic genes and citrate metabolism of prostate epithelial cells. Horm. Metab. Res. (2002) 34(8):417-424.
50. COSTELLO LC, FRANKLIN RB: Novel role of rinc in the regulation of prostate citrate metabolism and its implications in prostate cancer. Prostate (1998) 35(4):285-296.
51. COSTELLO LC, FRANKLIN RB: Citrate metabolism of normal and malignant prostate epithelial cells. Urology (1997) 50(1):3-12.
52. STONER E: Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology (1994) 43:284-289.
53. PEEHL DM, SKOWRONSKI RJ, LEUNG GK, WONG ST, STAMEY TA, FELDMAN D: Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res. (1994) 54:805-810.
54. CRESCIOLI C, MAGGI M, VANNELLI GB et al.: Effect of vitamin D3 analogue on keratinocyte growth factor-induced cell proliferation in benign prostatic hyperplasia. J. Clin. Endocrinol. Metab. (2000) 85(7):2576-2583.
55. DJONOV V, BALL RK, GRAF S et al.: Transforming growth factor-β3 is expressed in nondividing basal epithelial cells in normal human prostate and benign prostatic hyperplasia, and is no longer detectable in prostate carcinoma. Prostate (1997) 31:103-109.
56. BARRACK ER: TGF-β in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate (1997) 31(1):61-70.
57. SKOWRONSKI RJ, PEEHL DM, FELDMAN D: Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology (1993) 132:1952-1960.
58. WU-WONG JR, TIAN J, GOLTZMAN D: Vitamin D analogs as therapeutic agents: a clinical study update. Curr. Opin. Invest. Drugs (2004) 5(3):320-326.
59. CRESCIOLI C, MORELLI A, ADORINI L: Human bladder as a novel target for vitamin D receptor ligands. J. Clin. Endocrinol. Metab. (2005) 90(2):962-972.
60. EMONS G, GRÜNDKER C, GÜNTHERT AR, WESTPHALEN S, KARANAGH J, VERSCHRAEGEN C: GnRH antagonists in the treatment of gynecological and breast cancers. Endocrine-Related Cancer (2003) 10:291-299.
61. MAUDSLEY S, DAVIDSON L, PAWSON AJ, CHAN R, DE MATURANA RL, MILLAR RP: Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupled state of the type I GnRH receptor. Cancer Res. (2004) 64(20):7533-7544.
62. WHITTINGTON K, ASSINDER S, GOULD M, NICHOLSON H: Oxytocin, oxytocin-associated neurophysin and the oxytocin receptor in the human prostate. Cell Tissue Res. (2004) 318(2):375-382.
63. NICHOLSON HD: Oxytocin: a paracrine regulator of prostatic function. Rev. Reprod. (1996) 1(2):69-72.
64. REVERSI A, RIMOLDI V, MORROCCO T et al.: The oxytocin receptor antagonist atosiban inhibits cell growth via a 'biased agonist' mechanism. J. Biol. Chem. (2005) 280 (16):16311-16318.
65. ZHANG XH, FILLIPI S, VIGNOZZI L et al.: Identification, localization and functional in vitro and in vivo activity of oxytocin receptor in the rat penis. J. Endocrinol. (2005) 184(3):567-576.
66. STEINER MS, GINGRICH JR: Gene therapy for prostate cancer. Where are we now? J. Urol. (2000) 164(4):1121-1136.
67. SELKIRK SM: Gene therapy in clinical medicine. Postgrad. Med. J. (2004) 80(948):560-570.
68. LOWE FC, DREIKORN K, BORKOWSKI A et al.: Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH. Prostate (1998) 37(3):187-193.
69. BOYLE P, ROBERTSON C, LOWE F, ROEHRBORN C: Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int. (2004) 93(6):751-756.
70. DEBRUYNE F, KOCH G, BOYLE P et al.: Comparison of a phytotherapeutic agent (Permixon) with an α-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Prog. Urol. (2002) 12:384-392.
71. AUA PRACTICE GUIDELINES COMMITTEE: AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J. Urol. (2003) 170(2):530-547.
72. FOLEY CL, KIRBY RS: 5 α-reductase inhibitors: what's new? Curr. Opin. Urol. (2003) 13(1):31-37.
73. McDONALD H, HUX M, BRISSON M, BERNARD L, NICKEL JC: An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia. Can. J. Urol. (2004) 11(4):2327-2340.
74. SAVAGE SJ, SPUNGEN AM, GALEA G, BRITANICO J, VAPNEK JM: Combination medical therapy for symptomatic benign prostatic hyperplasia. Can. J. Urol. (1998) 5(3):578-584.
75. DEBRUYNE FM, JARDIN A, COLLOI D et al.: Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur. Urol. (1998) 34(3):169-175.
76. LEPOR H, WILLIFORD WO, BARRY MJ, HAAKENSON C, JONES K: The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. J. Urol. (1998) 160(4):1358-1367.
77. KIRBY RS, ROEHRBORN C, BOYLE P et al.: Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology (2003) 61(1):119-126.
78. McCONNELL JD, ROEHRBORN CG, BAUTISTA OM et al.: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med. (2003) 349:2387-2398.
79. DI SILVERIO F, BOSMAN C, SALVATORI M et al.: Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Eur. Urol. (2005) 47(1):72-78.
80. BALDWIN KC, GINSBERG PC, ROEHRBORN CG, HARKAWAY RC: Discontinuation of α-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology (2001) 58(2):203-209.
81. BARKIN J, GUIMARAES M, JACOBI G, PUSHKAR D, TAYLOR S, VAN VIERSSEN TRIP OB: α-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride. Eur. Urol. (2003) 44(4):461-466
82. ATHANASOPOULOS A, GYFTOPOULOS K, GIANNITSAS K, FISFIS J, PERIMENIS P, BARBALIAS G: Combination treatment with an α-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J. Urol. (2003) 169(6):2253-2256.
83. LEE JY, KIM HW, LEE SJ, KOH JS, SUH HJ, CHANCELLOR MB: Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int. (2004) 94(6):817-820.
84. 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-β signaling and IκBα induction. Br. J. Cancer. (2003) 88(10):1615-1621.
85. AUSTIN PF, COOK BL, NIEDERHOFF RA, MANSON SR, COPLEN DE, WEINTRAAB SJ: Inhibition of mitogenic signaling and induction of apoptosis in human bladder smooth muscle cells treated with doxazosin. J. Urol. (2004) 172(4):1662-1665.